INC Research Holdings, Inc. (SYNH)
(Delayed Data from NSDQ)
$47.27 USD
+0.56 (1.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.27 USD
+0.56 (1.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Implied Volatility Surging for Syneos Health (SYNH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Syneos Health (SYNH) stock based on the movements in the options market lately.
Syneos Health (SYNH) to Launch Serplulimab With New Pact
by Zacks Equity Research
Syneos Health's (SYNH) new partnership will develop an advanced commercialization model to serve healthcare professionals and patients in the best possible way in today's changing environment.
Syneos Health (SYNH) Hurt by Low Reimbursable Expense, FX Issue
by Zacks Equity Research
Syneos Health (SYNH) experiences delays in large pharma award decisions, with net awards being impacted by greater-than-normal delays.
Syneos Health (SYNH) to Enhance Clinical Trials With New Pact
by Zacks Equity Research
Syneos Health's (SYNH) extended partnership is part of the company's commitment to bringing clinical trials closer to the patient.
Syneos Health (SYNH) Q3 Earnings Miss Estimates, '22 View Cut
by Zacks Equity Research
Syneos Health (SYNH) Q3 revenues are below the guidance primarily due to the impact of lower net new business awards, delays in backlog conversion and customer delays in its FSP business.
1Life Healthcare, Inc. (ONEM) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
1Life Healthcare, Inc. (ONEM) delivered earnings and revenue surprises of -21.28% and 3.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
IRhythm Technologies (IRTC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 23.17% and 2.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Inspire (INSP) Soars 7.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Inspire (INSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here's Why Investors Should Retain Syneos Health (SYNH) for Now
by Zacks Equity Research
Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental results.
Syneos Health (SYNH) Q2 Earnings Top Estimates, Cuts '22 View
by Zacks Equity Research
Syneos Health (SYNH) posts better-than-expected earnings in the second quarter and robust results across the Clinical Solutions and Commercial Solutions businesses.
Syneos Health (SYNH) Beats Q2 Earnings Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 4.17% and 1.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AllScripts Healthcare (MDRX) Q2 Earnings Expected to Decline
by Zacks Equity Research
AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syneos Health (SYNH) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Investors Should Retain Syneos Health (SYNH) For Now
by Zacks Equity Research
Investors about optimistic about Syneos Health's (SYNH) robust segmental performance and earnings outlook.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.
Syneos Health (SYNH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Syneos Health (SYNH) delivered earnings and revenue surprises of 5.21% and 0.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Syneos Health (SYNH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CareCloud, Inc. (MTBC) Stock Jumps 15.5%: Will It Continue to Soar?
by Zacks Equity Research
CareCloud, Inc. (MTBC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Should Value Investors Pick Syneos Health (SYNH) Stock Now?
by Zacks Equity Research
Let's see if Syneos Health, Inc. (SYNH) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Syneos Health (SYNH) Clinical Solutions Arm Grows Amid Cost Woe
by Zacks Equity Research
Despite the near-term COVID-19 challenges, Syneos Health (SYNH) remains confident about the long-term strength of its business given the robust backlog and the unique market position.
Medtronic (MDT) Boosts Surgical Robotics Wing With New Deal
by Zacks Equity Research
According to Medtronic (MDT), Touch Surgery Enterprise is the first AI-powered platform of its kind for the operating room (OR). It is compatible with Medtronic's Hugo robotic-assisted surgery (RAS) system.
Here's Why You Should Retain Syneos Health (SYNH) For Now
by Zacks Equity Research
Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental performance.
4 Stocks in Spotlight With AI Making Inroads in MedTech
by Riya Anand
MedTech stocks like Medtronic (MDT), Stryker (SYK), Allscripts Healthcare Solutions (MDRX) and Syneos Health (SYNH) are evolving rapidly in the field of AI-driven technologies.